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a  b  s  t  r  a  c  t
INTRODUCTION:  Myeloid  Sarcoma  (MS)  or Granulocytic  Sarcoma  is  an uncommon  laryngeal  malignancy.
It may  arise from  myelodysplastic  syndromes,  malignancy  or de novo.  Presentation  in  the larynx  is  rare
and some  may  present  with Acute Myeloid  Leukaemia  (AML)  whereby  the  later  may  be  asymptomatic.
CASE  PRESENTATION:  A 44-year-old  South  East  Asian  lady presented  with  a six months  history  of hoarse-
ness,  shortness  of  breath,  reduced  exercise  tolerance,  weight  loss  and laryngeal  irritation.  Symptoms
progressed  to coughing  with  liquids  two  months  prior.  On  examination,  she  had  a resting  biphasic  stridor
and  laryngoscopy  revealed  right  immobile  vocal  cord  with  a ﬁrm  right  ventricle  mass  extending  into  the
right paraglottic  space.  She  was pale  and  haematology  investigations  revealed  microcytic  hypochromic
anaemia.  Magnetic  Resonance  Imaging  (MRI)  of the  neck  and  thorax  showed  thickening  of the  right  false
cord,  true  cord  and  aryepiglottic  fold.  A biopsy  taken  during  endolaryngeal  microsurgery  (ELMS)  con-
ﬁrmed  myeloid  sarcoma  of  the  right  ventricle  and para  glottic  mass.  Further  investigation  revealed  a
background  of  AML  and she  then  underwent  chemotherapy.
DISCUSSION:  MS  is a rarity  with  only  nine  reported  cases  between  the years  of 1954 until  2015.  Immuno-
histochemistry  and  immunophenotyping  are  deﬁnite  for diagnosis  conﬁrmation  as  MS cells  often  exhibit
myeloperoxidase  (MPO),  lymphocyte  common  antigen  (LCA)  and  CD117  markers.  MS is  treated  with  are
chemotherapy  (either  systemic  or intrathecal),  radiotherapy,  surgical  excision  or in  combination.  Sys-
temic  chemotherapy  has  better  efﬁcacy  and  prognosis  as compared  to localised  treatment  of  radiotherapy
or surgical  excision.  However,  there  has yet  to  be a  deﬁnitive  chemotherapy  protocol.  Prognosis  is poor
with a 5-year  survival  rate  of  48%.
CONCLUSION:  Although  laryngeal  MS is  a rare  phenomenon,  early  recognition  is key  and  patients  should
always  be  investigated  for an  underlying  myeloproliferative  or dysplastic  disease.
©  2016  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Myeloid Sarcoma (MS) of the larynx is a rare and uncommon
ype of laryngeal malignant tumour. They composed of immature
yeloid cells which are of the extramedullary type of neoplasm
1]. It was ﬁrst introduced by Burns in 1811 known as chloroma
r granulocytic sarcoma. The term “Chloroma” was  used due to its
ypical form of green colour that is imparted to the tissues as a
esult of the high concentration of myeloperoxidase found within
he immature cells [2]. It was further on referred as “Granulocytic
arcoma” in 1966 by Rapaport as not all cells are green; but 30%
re grey, white or brown depending on the state of oxidation of the
igmented enzymes [1,3].
It is said that this tumour is typically associated with liq-
id tumours of Acute Myeloid Leukaemia (AML), myelodysplastic
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syndromes, coinciding with systemic diseases or arising de novo
[1]. The exact incidence of myeloid sarcoma in the larynx is yet
unknown with a handful of reporting due to its rarity [2,3]. It has
no gender predilection, but it is more common in children than
adult population, with 60% of patients younger than 15 years old
[4].
Literature review suggests that myeloid sarcoma can be seen to
occur in any part of the organ, with otolaryngology, head and neck
regions being the frequently reported sites [2]. However, laryngeal
involvement is rarely associated with myeloid sarcoma [4,5].
Byrd et al. conducted a review of 154 cases of extramedullary
leukaemia revealed that skin was the commonest site followed by
lymph nodes, spine, small intestine, orbit and nasal sinuses [6].
Furthermore, Horny et al. presented a review of 170 cases of pri-
mary laryngeal involvement by haematological tumour, whereby
only one was  a myeloid sarcoma of the larynx.
The majority of patients diagnosed with myeloid sarcoma may
be asymptomatic of AML  [7]. However, in some cases, laryngeal
myeloid sarcoma may  precede and represent an initial manifesta-
tion of AML  by several months or years. The previous report has
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. This ﬁgure shows an image of MRI  of the patient’s neck in coronal view
depicting thickened right false cord, true cord and aryepiglottic fold (arrowed).
Fig. 2. This ﬁgure shows an endoscopic view of the patient’s larynx via ﬂexible








Fig. 3. This ﬁgure shows an endoscopic view of the patient’s larynx via direct laryn-
icap Index-10 (VHI-10) score was  of 24/40 and Eating Assessment
Tool-10 (EAT-10) score of 20/40 which were abnormal.ilateral subcordal edema (B). The left true cord is visualised (C).
lso shown that myeloid sarcoma may  develop in a patient with
elapse of previously treated AML.
This article discussed the rare and unusual occurrence of de novo
yeloid sarcoma of the larynx in middle-aged woman  who  pre-
ented with hoarseness and sudden onset of shortness of breath.
e have also discussed the common presenting symptoms and
urrent treatment protocol based on the available literature review.goscopy depicting the appearance after carbon dioxide laser biopsy of the right false
cord mass (A), laser ablation of the right subcordal edema (B) and dilatation of the
subcordal region (C).
2. Case report
A 44-year-old lady, South East Asian in ethnicity with no sig-
niﬁcant past medical history presented to the Otolaryngology
outpatient clinic with a six months history of hoarseness and
occasional loss of voice. She is a teacher by profession and her
hoarseness was exaggerated during voice straining at the class-
room. She complained of progressively worsening reduction in
effort tolerance, resulting in her being short of breath on per-
forming activities of daily living such as cooking and dressing.
There was  also signiﬁcant unintentional weight loss of 5 kilo-
grams over two months associated with loss of appetite. Moreover,
she complained of frequent laryngeal irritation for two months,
described as globus sensation in the throat resulting in recurrent
non-productive cough. This was  associated with occasional chok-
ing and coughing on swallowing liquids although she denied any
dysphagia or odynophagia.
She had no signiﬁcant past medical or surgical history. Four
months into her symptoms, she complained of breathing dif-
ﬁculties with noisy breathing. She was admitted to a district
hospital and was  treated for bronchial asthma. The earlier symp-
toms repeated itself two weeks later whereby she was readmitted
at the same hospital and nursed in the intensive care unit for an
acute exacerbation of bronchial asthma. An otolaryngology consult
was obtained and subsequently, she was  referred to UKM Medical
Centre, Kuala Lumpur for a tertiary care management.
On examination, she was  apyrexial and haemodynamically sta-
ble. There was audible biphasic stridor at rest, but she was  able
to count up to 10 in a single breath with no respiratory dis-
tress. The cardiopulmonary assessment was unremarkable. Flexible
nasopharyngolaryngoscopy revealed a bulky right false cord cov-
ering part of the true cord, with limited mobility of the right vocal
cord, and severe bilateral subcordal edema narrowing the airway
(Fig. 1). Her nasal and oral cavities were normal. Her Voice Hand-The haematological assessment was normal with the exception
of microcytic hypochromic anaemia with haemoglobin of 9.0 g/dl.
CASE  REPORT  –  OPEN  ACCESS























Cig. 4. (A, B) The tissue is inﬁltrated by sheets of small to medium sized dyscohesiv
hromatin, inconspicuous nucleoli and scanty cytoplasm. These cells are immunorea
eoplastic cells inﬁltration that displays similar morphology (F).
he immunological screening was negative of ANA, ANCA, rheuma-
oid factors and complement 3 and 4 proteins. Radiological imaging
howed unremarkable chest x-ray ﬁndings whilst Magnetic Reso-
ance Imaging (MRI) of the neck showed thickening of the right
alse cord, true cord and aryepiglottic fold, with edema of the sub-
lottis, consistent with our scope ﬁndings (Fig. 2).
She underwent an endolaryngeal microsurgery under general
naesthesia. Intra-operatively there was a ﬁrm mass arising from
he right ventricle extending into the right paraglottic space (Fig. 2).
he right subcordal mass was ablated using a carbon dioxide laser
nd subsequently dilated up to 30 French Bougie to improve the
irway (Fig. 3). Despite this, the patient developed a worsening
nspiratory stridor with tachypnoea on extubation six hours post-
rocedure necessitating an emergency tracheostomy.
Histological examination of the right false cord and paraglottic
asses showed sheets of small to medium-sized neoplastic cells
nﬁltrating the muscle ﬁbres. The neoplastic cells display round to
val nuclei with ﬁnely-dispersed chromatin, inconspicuous nucle-
li and scanty cytoplasm. Immunohistochemically, the neoplastic
ells are immunoreactive for LCA (strong and diffuse), MPO  (strong
nd diffuse) and CD117, and they are negative for CKAE1/AE3,
D20, Cd79a, CD3, CD34 and TdT (Fig. 4). She was then investigatedplastic cells. The neoplastic cells display round to oval nuclei with ﬁnely-dispersed
toward LCA (C), CD117 (D) and MPO  (E). Bone marrow trephine biopsy also showed
for myeloproliferative disease in which bone marrow biopsy and
trephine conﬁrmed a primary AML. She had received chemother-
apy with High Dose Cytosine Arabinoside (HiDAC) protocol. After
a cycle of chemotherapy, the mass on the right false cord and
bilateral severe subcordal edema were not visualised on a repeat
ﬂexible scope (Fig. 5). She developed neutropenic sepsis and inva-
sive pulmonary aspergilosis. Repeat bone marrow biopsy showed
refractory AML. She passed away several months later. This work
has been reported in line with the CARE criteria [8].
3. Discussion
This case reports a 44-year-old lady with no history of AML,
myelodysplastic syndromes or systemic diseases was unexpectedly
diagnosed with MS  of larynx as per histopathology and immuno-
histochemistry examination. MS  are relatively uncommon, and
laryngeal involvement is even more so, thus it is important for oto-
laryngologists to be aware of the possible presenting symptoms,
site of involvement and management of these tumours. We  identi-
ﬁed only nine cases being reported between 1954 until 2015 by
using PubMed and MEDLINE search with keywords of ‘myeloid,
sarcoma, larynx’. Presenting symptoms and signs, and treatments
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Table 1
This table shows summary of 5 cases being reported with the keyword of ‘myeloid; sarcoma; larynx’ in PubMed/Medine search.
Cases History at presentation Clinical features Deﬁnitive treatment
1 On remission 37, male. Dysphagia and hoarseness
Multiple unilateral lower cranial nerve
paralysis—IX, X, XII. Multiple masses involving
larynx and nasopharynx
Chemotherapy
Outcome: patient died due to pulmonary infection on day
17  of chemotherapy
2  No history 32, male. Hoarseness
Ulcerative mass on left laryngeal surface of
epiglottis, aryepiglottic fold and vocal cord with
immobile left vocal cord
Chemotherapy
Outcome: patient died 2 months after commencement of
chemotherapy
3  Relapsed 3 months post radiation 57, male. Respiratory distress, requiring
tracheostomy
Right laryngeal mass involving true and false vocal
cords and subglottis that was partially occluding
the  airway
Radiation therapy of 24 Gy in 12 fractions
Outcome: disease free for 3 months, subsequently
sufferred systemic progression and not ﬁt for additional
systemic therapies, and passed away several weeks later
4  No history 36, male. Dysphagia, hoarseness and stridor
requiring tracheostomy.
Submucosal mass on right false cord partially
obstructing the airway
Induction chemotherapy followed by consolidation
chemotherapy
Outcome: developed recurrence of disease despite
completion of chemotherapy treatment
5  CML detected by bone marrow aspiration 50, male. Hoarseness and worsening sore throat
Clinical ﬁndings not documented
Treatment and outcome were not reported
Fig. 5. This ﬁgure shows an endoscopic view of the patient’s larynx via ﬂexible
nasopharyngolaryngoscopy depicting a clear view of the vocal cords with no sub-

















This table shows treatment approach for MS obtained from Vishnu et al. with per-
mission [15].
Disease status Suggested treatment approach
Isolated GS
GS with bone marrow involvement
Relapsed isolated GS after
chemotherapy
Relapsed GS and bone marrow disease
after chemotherapy
Relapse of isolated GS after AHSCT
Relapse of concurrent GS and bone
marrow disease after AHSCT
Chemotherapy followed by
surgery/radiation treatment
Chemotherapy with consideration for
AHSCT
Chemotherapy followed by AHSCT
Chemotherapy followed by AHSCT
Donor lymphocyte infusion, tapering
of immunosuppression if tolerated, or
investigational agent versus palliative
IDRT
Investigational agents versus best
supportive care
MS patients receiving systemic chemotherapy by 42% comparedhemotherapy. The right(A) and left (B) true cord are visualized.
elivered to these patients are summarised in Table 1. However,
nly ﬁve cases were tabled as the remaining four cases described
he disease per se, omitting symptoms and signs.
Of the ﬁve cases being shown in Table 1, majority of patients
o not have underlying medical illness. All patients presented with
ymptoms of hoarseness, two of them complicated with respira-
ory distress requiring an emergency tracheostomy for obstruction
elieve. Three of the ﬁve cases underwent chemotherapy and one
nderwent radiotherapy. However, most of the patients passed
way due to disease progression or suffered from systemic infec-
ion. To our knowledge, this case report is the second case that
resented de novo with upper airway obstruction (Table 2).
MS  is often misdiagnosed as the common alternative diagno-
is of being either a lymphoma or undifferentiated carcinoma [9].
isdiagnosis may  be due to an incomplete work-up which may  be
isleading because T-cell or B-cell lymphoma and MS  share similarAbbreviations:  AHSCT; allogeneic hematopoietic stem cell transplant; GS, granulo-
cytic sarcoma; IFRT, involved-ﬁeld radiotherapy.
morphologic patterns and both express leucocyte speciﬁc antigens
[6].
The best deﬁnitive diagnosis is via immunohistochemistry and
immunophenotyping. According to WHO  2008 classiﬁcation, cyto-
chemical stains should be myeloperoxidase (MPO), lymphocyte
common antigen (LCA) and CD117 [10]. CD 117 and MPO  are the
most common markers in ﬂow cytometric analysis in tumours
to have a strong positive staining with myeloid differentiation.
Our patient showed a strong positive staining to LCA, MPO  and
CD 99 with positive CD 68 and CD 117 over the focal granular
region. These malignant cells also show a high proliferative index
of Ki67 being over 80%. Other common markers are CD68/PG-M1,
CD34, terminal-deoxy-nucleotidyl-transferase, CD56, CD61, CD30
and CD4 [11].
Treatment options depends upon patient, tumour factors and
disease characteristics. There are several important factors for con-
sideration, which includes the patient’s age, associated medical
comorbidities, clinical symptoms, tumour type and stage and lastly,
the extent of the disease involvement. Treatments employed for MS
are chemotherapy (either systemic or intrathecal), radiotherapy,
surgical excision or a combination of these interventions (Table 1).
Literature review suggests that current treatment options are
conventional chemotherapeutic protocol for AML [5]. Tsimberidou
et al. showed reduction in rate of progression to AML  in isolatedto patients receiving tumour localized treatment [12]. Isolated
MS patients treated with AML  based induction regimens have
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een reported to share similar prognostic features and prolonged
isease-free interval [13].
Literature review is lacking evidence for a deﬁnite form of
hemotherapeutic regime in treating MS.  More data is required on
he efﬁcacy of speciﬁc chemotherapeutic regime used and follow up
n term of prognostic factors and disease free survival period. Radio-
herapy is often given concurrently with systemic chemotherapy
lthough its role is not well established. Tsimberidou et al. found
o difference on survival rate in isolated MS  patients treated with
adiotherapy in addition to chemotherapy or chemotherapy as a
tandalone [12]. Another recent article by Hoover et al., reported
hat MS  is generally radiosensitive. The authors recommended
reatment of minimum 20 Gy and proposed a regime of 24 Gy over
2 fractions as an appropriate treatment course for laryngeal MS
2].
The overall prognosis is poor in patients who were diagnosed
ith myeloid sarcoma with 53% mortality rate and an average life
xpectancy of patients with AML  diagnosed with MS  is less than
2 months [14]. This was  seen is our patient. A retrospective study
f 51 patients with myeloid sarcoma, either isolated or associated
ith AML  showed a 5-year overall survival rate of 48%, with no
igniﬁcant differences in outcomes between the two presentations
15].
. Conclusion
This case report and literature appraisal can conclude four main
oints. Firstly, laryngeal MS  is of rare occurrence and may  be
symptomatic of haematological manifestations. Early recognition
or laryngeal MS  is key with high suspicions amongst patients
resenting with haematological disorders. Secondly, MS  responds
ore favourably to systemic chemotherapy with or without radio-
herapy compared to surgical treatment alone. Thirdly, the role of
urgical treatment in laryngeal MS  is mainly for biopsy and relieve
f upper airway obstruction. Lastly, MRI  of the larynx may  not be
peciﬁc but may  be useful in diagnosis.
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